Vinay Prasad will leave FDA CBER by end of April, returning to UCSF after a one-year sabbatical, following a prior departure ...

European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...

Teclistamab plus daratumumab gains FDA approval for relapsed/refractory multiple myeloma, showing 83% reduction in disease progression versus standard care.

AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.

Developments across the sector highlight a period of rapid acceleration and structural modernization. Welcome back to the PharmTech Weekly Roundup! I’m Susan Haigney, lead editor of PharmTech. There ...

As sponsors advanced more niche and personalized modalities, manufacturers were pushed to adopt holistic approaches to safety ...

FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

Click here to view the Pharmaceutical Technology Europe TM September/October 2025 issue.

US early-phase trial velocity is constrained by hospital contracting, IRB workflows, and IND review timelines, elevating the ...

FDA enforcement accelerated, with recent warning-letter volume exceeding the prior decade’s total, signaling a sustained departure from historical, reactive promotional oversight. “Sameness” ...

FDA granted full approval to teclistamab plus daratumumab/hyaluronidase for RRMM after ≥1 prior line, marking first bispecific T-cell engager conversion from ...